keyword
MENU ▼
Read by QxMD icon Read
search

Lansoprazole

keyword
https://www.readbyqxmd.com/read/28088896/formulation-and-optimization-of-lansoprazole-pellets-using-factorial-design-prepared-by-extrusion-spheronization-technique-using-carboxymethyl-tamarind-kernel-powder
#1
Sagar Sopanrao Muley, Tanaji Nandgude, Sushilkumar Poddar
BACKGROUND: In the present study, Lansoprazole pellets were prepared employing a novel excipient Carboxymethyl tamarind kernel powder (CMTKP) using extrusion-spheronization technique. Pellet formulation was optimized for formulation parameters (concentration of microcrystalline cellulose, CMTKP, croscarmellose sodium and isopropyl alcohol). METHODS: Process parameters (speed and duration of spheronization) were optimized using factorial design. The pellets were evaluated for yield, bulk and tapped density, particle size, hardness, drug content, disintegration time and drug release...
January 13, 2017: Recent Patents on Drug Delivery & Formulation
https://www.readbyqxmd.com/read/28039570/different-transcriptional-profiling-between-senescent-and-non-senescent-human-coronary-artery-endothelial-cells-hcaecs-by-omeprazole-and-lansoprazole-treatment
#2
Laura Costarelli, Robertina Giacconi, Marco Malavolta, Andrea Basso, Francesco Piacenza, Mauro Provinciali, Marcello G Maggio, Andrea Corsonello, Fabrizia Lattanzio
Recent evidence suggests that high dose and/or long term use of proton pump inhibitors (PPIs) may increase the risk of adverse cardiovascular events in older patients, but mechanisms underlying these detrimental effects are not known. Taking into account that the senescent endothelial cells have been implicated in the genesis or promotion of age-related cardiovascular disease, we hypothesized an active role of PPIs in senescent cells. The aim of this study is to investigate the changes in gene expression occurring in senescent and non-senescent human coronary artery endothelial cells (HCAECs) following Omeprazole (OPZ) or Lansoprazole (LPZ) treatment...
December 30, 2016: Biogerontology
https://www.readbyqxmd.com/read/27991740/determination-of-rabeprazole-enantiomers-in-dog-plasma-by-supercritical-fluid-chromatography-tandem-mass-spectrometry-and-its-application-to-a-pharmacokinetic-study
#3
Chong Su, Hong Yang, Xiangjun Meng, J Paul Fawcett, Jianming Cao, Yan Yang, Jingkai Gu
Rabeprazole is a novel benzimidazole proton pump inhibitor used for the treatment of gastrointestinal disorders. It is a chiral molecule that gives rise to the possibility of stereoselective pharmacokinetics. To investigate this phenomenon, a rapid and sensitive chiral assay based on supercritical fluid chromatography tandem mass spectrometry was developed and applied to the determination of (R)-rabeprazole and (S)-rabeprazole in dog plasma. Sample preparation involved protein precipitation with acetonitrile after addition of (R)-lansoprazole as internal standard...
December 19, 2016: Journal of Separation Science
https://www.readbyqxmd.com/read/27988924/successful-eradication-therapy-for-helicobacter-pylori-positive-atrophic-gastritis-at-the-sixth-attempt-a-case-report
#4
Ryuzo Deguchi, Koichi Shiraishi, Yoshitaka Arase, Makiko Dekiden, Hideo Shimada, Hiroshi Miyakita, Takashi Ogimi, Kazunori Myojin, Tetsuya Mine
A 74-year-old woman undergoing outpatient follow-up for reflux esophagitis and atrophic gastritis tested positive for Helicobacter pylori and underwent primary eradication therapy with lansoprazole (LPZ) 30 mg, amoxicillin (AMPC) 750 mg, and clarithromycin (CAM) 200 mg twice daily for 1 week in August 2012. A urea breath test (UBT) after this treatment revealed that eradication had failed. Secondary eradication therapy was carried out with esomeprazole (EPZ) 20 mg, AMPC 750 mg, and metronidazole (MNZ) 250 mg twice daily for 1 week, but this also failed...
December 20, 2016: Tokai Journal of Experimental and Clinical Medicine
https://www.readbyqxmd.com/read/27981489/influence-of-low-dose-proton-pump-inhibitors-administered-concomitantly-or-separately-on-the-anti-platelet-function-of-clopidogrel
#5
Takahisa Furuta, Mitsushige Sugimoto, Chise Kodaira, Masafumi Nishino, Mihoko Yamade, Takahiro Uotani, Shu Sahara, Hitomi Ichikawa, Takuma Kagami, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Ken Sugimoto, Kazuo Umemura
Proton pump inhibitors (PPIs) at low doses can effectively prevent gastrointestinal bleeding due to aspirin and are widely used in Japan for gastroprotection in patients taking anti-platelet agents. We examined the influence of different PPIs at low doses administered concomitantly or separately on anti-platelet functions of clopidogrel. In 41 healthy Japanese volunteers with different CYP2C19 genotypes who took clopidogrel 75 mg in the morning alone, or with omeprazole 10 mg, esomeprazole 10 mg, lansoprazole 15 mg, or rabeprazole 10 mg, either concomitantly in the morning or separately in the evening, we measured the inhibition of platelet aggregation (IPA, %) using VerifyNow P2Y12 assay at 4 h after the last clopidogrel dose on Day 7 of each regimen...
December 15, 2016: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/27937036/gastroprotective-activity-of-the-resin-from-virola-oleifera
#6
Ana Claudia Hertel Pereira, Dominik Lenz, Breno Valentim Nogueira, Rodrigo Scherer, Tadeu Uggere Andrade, Helber Barcellos da Costa, Wanderson Romão, Thiago Melo Costa Pereira, Denise Coutinho Endringer
CONTEXT: The resin from the trunk wood of Virola oleifera (Schott) A. C. Smith (Myristicaceae) is used in folk medicine to hasten wound repair and to treat pain and inflammatory conditions, and our previous report indicated the anti-oxidative properties in other oxidative stress model. OBJECTIVE: To investigate the protective effects of resin from V. oleifera in two experimental models of gastric ulcer oxidative-stress dependent. MATERIALS AND METHODS: Plant material was collected and the resin was subjected to partitioning with organic solvents...
December 2017: Pharmaceutical Biology
https://www.readbyqxmd.com/read/27926505/antitumor-effect-of-combination-of-the-inhibitors-of-two-new-oncotargets-proton-pumps-and-reverse-transcriptase
#7
Luana Lugini, Ilaria Sciamanna, Cristina Federici, Elisabetta Iessi, Enrico Pierluigi Spugnini, Stefano Fais
Tumor therapy needs new approaches in order to improve efficacy and reduce toxicity of the current treatments. The acidic microenvironment and the expression of high levels of endogenous non-telomerase reverse transcriptase (RT) are common features of malignant tumor cells. The anti-acidic proton pump inhibitor Lansoprazole (LAN) and the non-nucleoside RT inhibitor Efavirenz (EFV) have shown independent antitumor efficacy. LAN has shown to counteract drug tumor resistance. We tested the hypothesis that combination of LAN and EFV may improve the overall antitumor effects...
December 3, 2016: Oncotarget
https://www.readbyqxmd.com/read/27909552/vonoprazan-20-mg-vs-lansoprazole-30-mg-for-endoscopic-submucosal-dissection-induced-gastric-ulcers
#8
Kazuya Takahashi, Yuichi Sato, Junji Kohisa, Jun Watanabe, Hiroki Sato, Kenichi Mizuno, Satoru Hashimoto, Shuji Terai
AIM: To compare the healing effects of vonoprazan and lansoprazole on gastric ulcers induced by endoscopic submucosal dissection (ESD). METHODS: Data were obtained from a total of 26 patients. Fourteen patients were randomized to the vonoprazan group and 12 were randomized to the lansoprazole group. Patients were administered either 20 mg vonoprazan or 30 mg lansoprazole per day after ESD. Endoscopic images just after ESD, on day 8, and on day 28 were used for the evaluation of the shrinking rate of ESD ulcers...
November 16, 2016: World Journal of Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/27891632/randomised-clinical-trial-efficacy-and-safety-of-vonoprazan-vs-lansoprazole-in-patients-with-gastric-or-duodenal-ulcers-results-from-two-phase-3-non-inferiority-randomised-controlled-trials
#9
H Miwa, N Uedo, J Watari, Y Mori, Y Sakurai, Y Takanami, A Nishimura, T Tatsumi, N Sakaki
BACKGROUND: Vonoprazan is a new potassium-competitive acid blocker for treatment of acid-related diseases. AIM: To conduct two randomised-controlled trials, to evaluate the non-inferiority of vonoprazan vs. lansoprazole, a proton pump inhibitor, for treatment of gastric ulcer (GU) or duodenal ulcer (DU). METHODS: Patients aged ≥20 years with ≥1 endoscopically-confirmed GU or DU (≥5 mm white coating) were randomised 1:1 using double-dummy blinding to receive lansoprazole (30 mg) or vonoprazan (20 mg) for 8 (GU study) or 6 (DU study) weeks...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27883262/phytochemicals-enhance-antioxidant-enzyme-expression-to-protect-against-nsaid-induced-oxidative-damage-of-the-gastrointestinal-mucosa
#10
REVIEW
Yu-Ting Cheng, Chi-Cheng Lu, Gow-Chin Yen
The gastrointestinal mucosa provides the first protective barrier for digested food and xenobiotics, which are easily attacked by toxic substances. Non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, diclofenac, indomethacin, and ketoprofen, are widely used in clinical medicine, but these drugs may cause oxidative stress, leading to gastrointestinal damage, such as ulcers. Lansoprazol, omeprazole, and other clinical drugs are widely used to treat duodenal and gastric ulcers and haven been shown to have multiple biological functions, such as antioxidant activity and the ability to upregulate antioxidant enzymes in vivo...
November 24, 2016: Molecular Nutrition & Food Research
https://www.readbyqxmd.com/read/27875029/decreased-activity-and-genetic-polymorphisms-of-cyp2c19-in-beh%C3%A3-et-s-disease
#11
Mustafa Tugrul Goktas, R Ozgur Karaca, Said Kalkisim, Lokman Cevik, Levent Kilic, Ali Akdogan, Melih O Babaoglu, Atilla Bozkurt, Leif Bertilsson, Umit Yasar
Behçet's disease (BD) is a systemic autoimmune disorder. Cytochrome P450 enzymes (CYPs) are responsible for various drug metabolism reactions as well as those of endogenous substances which may be associated with autoimmune disease susceptibility. Recently, we reported that in patients with BD, CYP2C9 seems to be down-regulated due to inflammation. In the same Turkish BD patients, we investigated whether also CYP2C19 activity is decreased. Lansoprazole (30 mg) was given as a probe drug to evaluate CYP2C19 activity in 59 patients with BD and 27 healthy control volunteers...
November 22, 2016: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/27843960/addition-of-cranberry-to-proton-pump-inhibitor-based-triple-therapy-for-helicobacter-pylori-eradication
#12
Mohammadreza Seyyedmajidi, Anahita Ahmadi, Shahin Hajiebrahimi, Seyedali Seyedmajidi, Majid Rajabikashani, Mona Firoozabadi, Jamshid Vafaeimanesh
OBJECTIVE: Proton pump inhibitor-based triple therapy with two antibiotics for Helicobacter pylori eradication is widely accepted, but this combination fails in a considerable number of cases. Some studies have shown that cranberry inhibits the adhesion of a wide range of microbial pathogens, including H. pylori. The aim of this study was to assess the effect of cranberry on H. pylori eradication with a standard therapy including lansoprazole, clarithromycin, and amoxicillin (LCA) in patients with peptic ulcer disease (PUD)...
October 2016: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/27810240/gastroprotective-activity-of-synthetic-coumarins-role-of-endogenous-prostaglandins-nitric-oxide-non-protein-sulfhydryls-and-vanilloid-receptors
#13
Beatriz Sepulveda, Cristina Quispe, Mario Simirgiotis, Alfredo Torres-Benítez, Johanna Reyes-Ortíz, Carlos Areche, Olimpo García-Beltrán
Natural or synthetic coumarins showed gastroprotective and antiulcer activity in animal models. In this study, we have synthetized twenty coumarins using classic methods to evaluate their gastroprotective effects on the ethanol/HCl-induced gastric lesion model in mice at 20mg/kg. Among the coumarins synthetized, compounds 6 and 10 showed the greatest gastroprotective activity being as active as lansoprazole at 20mg/kg and reducing gastric lesions by 75 and 76%, respectively. Then, in a second experiment, compounds 6 and 10 were re-evaluated in order to understand the possible mode of gastroprotective activity...
October 22, 2016: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/27797279/investigation-of-the-bioequivalence-of-two-lansoprazole-formulations-in-healthy-chinese-volunteers-after-a-single-oral-administration
#14
Yuhai Bian, Ming Zhong
The objective of this study was to compare two lansoprazole products (the reference brand enteric-coated capsules and the test generic enteric-coated tablets), and the key pharmacokinetic (PK) parameters for both formulations and their metabolites were assessed. The study used an open-label, randomized two-period crossover design with an 8-day washout period between doses in 24 healthy subjects under fasting conditions. The concentration of lansoprazole and its two metabolites was determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS) method...
October 31, 2016: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/27782887/comparison-of-the-effects-of-esomeprazole-40-mg-rabeprazole-20-mg-lansoprazole-30-mg-and-pantoprazole-40-mg-on-intragastr%C3%A4-c-ph-in-extensive-metabolizer-patients-with-gastroesophageal-reflux-disease
#15
Altay Çelebi, Dinçer Aydın, Orhan Kocaman, Buğra Tolga Konduk, Ömer Şentürk, Sadetin Hülagü
BACKGROUND/AIMS: Studies on the therapeutic efficacy of proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD) have been recently published. In most of these studies, comparison of only two PPIs have been made. There are few studies on the comparison of four or more PPIs. We aimed to compare the acid inhibitory effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on days 1 and 5 of treatment in patients with GERD, who were extensive metabolizers in regard to the CYP2C19 genotype...
September 2016: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/27769562/concomitant-bismuth-quadruple-and-14-day-triple-therapy-in-the-first-line-treatment-of-helicobacter-pylori-a-multicentre-open-label-randomised-trial
#16
Jyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, Ming-Jong Bair, Chi-Yang Chang, Yi-Chia Lee, Mei-Jyh Chen, Chien-Chuan Chen, Cheng-Hao Tseng, Yao-Chun Hsu, Ji-Yuh Lee, Tsung-Hua Yang, Jiing-Chyuan Luo, Chun-Chao Chang, Chi-Yi Chen, Po-Yueh Chen, Chia-Tung Shun, Wen-Feng Hsu, Wen-Hao Hu, Yen-Nien Chen, Bor-Shyang Sheu, Jaw-Town Lin, Jeng-Yih Wu, Emad M El-Omar, Ming-Shiang Wu
BACKGROUND: Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori. METHODS: In this multicentre, open-label, randomised trial, we recruited adult patients (aged >20 years) with H pylori infection from nine medical centres in Taiwan...
November 12, 2016: Lancet
https://www.readbyqxmd.com/read/27748322/inefficacy-of-triple-therapy-and-comparison-of-two-different-bismuth-containing-quadruple-regimens-as-a-firstline-treatment-option-for-helicobacter-pylori
#17
Murat Kekilli, Ibrahim K Onal, Serkan Ocal, Zeynal Dogan, Alpaslan Tanoglu
BACKGROUND/AIM: Increasing resistance of Helicobacter pylori to antimicrobials necessitated the development of new regimens and the modification of existing regimens. The present study aimed to compare the efficacy of two bismuth-containing quadruple regimens-one including clarithromycin (C) instead of metronidazole (M) and triple therapy. PATIENTS AND METHODS: Patients with H. pylori infection given the following regimens were sequentially enrolled in this retrospective study: (1) Triple therapy: Lansoprazole 30 mg b...
September 2016: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/27737742/coupling-data-mining-and-laboratory-experiments-to-discover-drug-interactions-causing-qt-prolongation
#18
Tal Lorberbaum, Kevin J Sampson, Jeremy B Chang, Vivek Iyer, Raymond L Woosley, Robert S Kass, Nicholas P Tatonetti
BACKGROUND: QT interval-prolonging drug-drug interactions (QT-DDIs) may increase the risk of life-threatening arrhythmia. Despite guidelines for testing from regulatory agencies, these interactions are usually discovered after drugs are marketed and may go undiscovered for years. OBJECTIVES: Using a combination of adverse event reports, electronic health records (EHR), and laboratory experiments, the goal of this study was to develop a data-driven pipeline for discovering QT-DDIs...
October 18, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27733667/association-between-proton-pump-inhibitors-and-microscopic-colitis-implications-for-practice-and-future-research
#19
REVIEW
Ernest H Law, Melissa Badowski, Yu-Ting Hung, Kimberly Weems, Angelica Sanchez, Todd A Lee
OBJECTIVE: Microscopic colitis (MC) is a chronic inflammatory disease of the colon that is characterized by chronic, watery, nonbloody diarrhea. Concern regarding a potential association between proton-pump inhibitors (PPIs) and MC has recently emerged. We sought to systematically review and summarize the evidence for the potential association between PPIs and MC. DATA SOURCES: We systematically searched EMBASE, MEDLINE, Cochrane Database of Systematic Reviews, International Pharmaceutical Abstracts, and Google Scholar using the terms proton-pump inhibitors (omeprazole, lansoprazole, dexlansoprazole, rabeprazole, pantoprazole, or esomeprazole), microscopic colitis, collagenous colitis, and lymphocytic colitis STUDY SELECTION: Full-text, English-language reports of case reports/series, observational studies, experimental studies, and systematic reviews/meta-analyses published between January 2000 to August 2016 were included...
October 12, 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/27683046/stereoselective-pharmacodynamics-and-pharmacokinetics-of-proton-pump-inhibitors
#20
REVIEW
Zhi-Cheng Yang, Feng Yu, Yong-Qing Wang, Ji-Fu Wei
BACKGROUND: Proton pump inhibitors (PPIs) are a group of gastric acid suppressing drugs, they work by irreversibly blocking the H+/K+ ATPase. The structure of PPIs is similar. They all have a similar core with a sulphur atom chiral center combined with different substituent groups. In relation to the sulphur atom chiral center, the pharmacodynamics, pharmacokinetics are diverse between the racemates and their stereoisomers. But there are no reviews outlining the stereoselective pharmacodynamics and pharmacokinetics in PPIs...
2016: Current Drug Metabolism
keyword
keyword
3617
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"